16:35 EST Spyre Therapeutics (SYRE) files automatic mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics Accelerates SKYLINE Trial and Bolsters Leadership
- Spyre Therapeutics highlights 2026 priorities, appoints Cheveln as CCO
- Spyre Therapeutics: TL1A Blockade Opportunity in Rheumatology Underpins Buy Rating and $64 Target
- Spyre Therapeutics falls -7.4%
- Spyre Therapeutics: TL1A-Driven Inflammatory Arthritis Opportunity Underpins Buy Rating and $64 Target